Alphatec Holdings, Inc. ATEC R2KR3KPHARMA
Company Overview
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.
Why Investors Should Care
Revenue has grown at a 12.2% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $764.15M (+25.0% YoY); net profit $-143.36M.
- Trailing 12 Months Year-on-year growth — revenue +15.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.23% |
| 1 Year: | 15.10% |
Stock Price Performance
| 1 Year: | -40.19% |
| 6 Months: | -22.73% |
| 3 Months: | +18.12% |
| 1 Month: | +2.61% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.97 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 58.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATEC Alphatec Holdings, Inc. R2KR3KPHARMA | 9.45 | -13.31 | $1.45B | 0.00% | -10.13% | - | 12.23% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.01M | 53.63M | 35.58M | 32.33M | 31.69M | 34.79M | 34.21M | 32.24M | 26.71M | 27.09M | 27.98M | 24.38M | 23.10M | 21.31M | 22.04M | 23.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 169.18M | 185.54M | 196.50M | 212.93M | 192.11M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.18M | 56.44M | 59.20M | 63.44M | 55.63M | - |
| Gross Profit | 36.31M | 37.69M | 24.49M | 18.29M | 21.66M | 23.59M | 24.49M | 21.16M | 15.86M | 14.63M | 16.78M | 15.75M | 14.51M | 14.90M | 15.55M | 16.21M | 16.57M | 18.89M | 19.93M | 21.03M | 20.84M | 29.24M | 31.86M | 41.06M | 39.61M | 49.22M | 55.48M | 59.52M | 70.42M | 64.54M | 80.05M | 97.35M | 102.59M | 102.73M | 116.00M | 129.10M | 137.30M | 149.49M | 136.48M | 154.10M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 147.70M | 140.59M | 146.71M | 154.85M | 158.53M | - |
| Operating Income | 1.73M | - | 1.14M | -2.83M | -164.68M | - | -3.44M | -320.00K | -4.55M | - | -3.40M | -735.00K | -1.26M | -667.00K | -6.54M | -7.53M | -10.77M | -10.41M | -11.60M | -17.81M | -11.16M | -12.86M | -19.05M | -35.75M | -35.12M | -41.23M | -35.75M | -34.97M | -40.35M | -49.86M | -38.36M | -43.34M | -35.31M | -33.70M | -31.71M | -11.48M | -9.41M | -5.36M | -22.06M | -1.91M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.95M | -8.35M | 4.75M | 11.63M | -1.68M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.84M | 12.31M | 12.88M | 12.89M | 11.72M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -51.97M | -41.18M | -28.50M | -21.75M | -33.86M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -64.00K | -37.00K | 74.00K | -18.00K | 50.00K | - |
| Net Income | -3.04M | -273.00K | -4.56M | -3.95M | -160.26M | -9.90M | -6.62M | -5.23M | -13.72M | -4.35M | -5.51M | -2.70M | -3.14M | -1.92M | -7.08M | -9.36M | -12.97M | -12.44M | -14.57M | -20.72M | -15.80M | -15.67M | -22.90M | -38.20M | -43.03M | -42.62M | -37.10M | -36.79M | -43.53M | -51.38M | -42.65M | -48.49M | -40.68M | -39.62M | -51.91M | -41.14M | -28.58M | -21.73M | -33.91M | -25.78M |
| Diluted EPS | -0.04 | -0.03 | -0.05 | -0.04 | -1.61 | -0.10 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.39 | -0.43 | -0.43 | -0.36 | -0.35 | -0.40 | -0.43 | -0.35 | -0.34 | -0.29 | -0.28 | -0.35 | -0.27 | -0.19 | -0.14 | -0.22 | -0.16 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 120.62M | 171.61M | 197.71M | 196.28M | 204.72M | 154.62M | 134.39M | 120.25M | 101.74M | 91.69M | 113.43M | 144.86M | 243.21M | 350.87M | 482.26M | 611.56M | 764.15M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 117.81M | 172.06M | 187.30M | 232.27M |
| Gross Profit | 81.01M | 112.82M | 116.93M | 123.77M | 124.32M | 109.67M | 88.02M | 76.13M | 68.22M | 63.24M | 77.59M | 102.50M | 157.76M | 233.06M | 310.20M | 424.26M | 531.89M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 354.16M | 458.48M | 547.17M | 589.85M |
| Operating Income | -10.19M | -11.79M | -24.52M | -9.84M | -73.43M | 1.49M | -175.85M | -15.38M | -9.00M | -22.44M | -47.28M | -58.86M | -128.06M | -121.10M | -148.28M | -122.91M | -57.97M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -102.58M | -110.59M | -53.87M | -14.92M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.50M | 16.64M | 24.88M | 45.92M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -152.01M | -186.91M | -162.07M | -143.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | -716.00K | -277.00K | 50.00K | -45.00K |
| Net Income | -13.29M | -14.36M | -22.18M | -15.46M | -82.23M | -12.88M | -178.68M | -29.93M | -2.29M | -28.98M | -57.00M | -78.99M | -143.03M | -151.29M | -186.64M | -162.12M | -143.36M |
| Diluted EPS | - | - | - | -0.17 | -0.85 | -1.90 | -21.53 | -3.49 | -1.08 | -1.20 | - | -1.18 | -1.49 | -1.47 | -1.54 | -1.13 | -0.96 |
| R&D Expense | 13.49M | 16.43M | 16.89M | 14.89M | 14.19M | 16.80M | 17.77M | - | - | - | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 377.02M | 366.69M | 382.13M | 365.63M | 344.92M | 146.34M | 94.19M | 84.66M | 129.48M | 169.95M | 261.22M | - | 520.97M | 805.21M | 775.71M | 791.21M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 255.63M | 451.09M | 417.40M | 450.88M |
| Cash & Equivalents | 18.32M | 10.09M | 23.17M | 20.67M | 22.24M | 21.34M | 19.73M | 11.23M | 19.59M | 22.47M | 29.05M | - | 107.77M | - | 84.70M | 220.97M | 138.84M | 160.81M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 101.52M | 136.84M | 175.26M | 169.44M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 60.06M | 72.61M | 82.99M | 97.30M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 555.63M | 727.09M | 789.88M | 778.78M |
| Current Liabilities | - | - | 43.59M | 57.14M | 56.79M | 79.72M | 63.60M | 125.04M | 40.13M | 29.74M | 30.61M | 36.39M | 58.31M | - | 138.87M | 157.57M | 153.03M | 219.18M |
| Long Term Debt | - | - | 32.47M | 23.80M | 39.97M | 49.98M | 74.60M | 480.00K | 43.09M | 37.77M | 42.30M | 53.45M | 38.00M | - | 349.51M | 511.04M | 574.52M | 501.41M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 395.86M | 541.68M | 609.94M | 596.09M |
| Total Equity | 71.47M | 74.83M | 266.43M | 245.33M | 245.82M | 171.68M | 148.95M | -36.58M | -41.50M | -26.66M | 17.57M | 43.63M | 129.88M | - | -34.67M | 78.12M | -14.17M | 12.43M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 108.45M | 141.05M | 145.94M | 150.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.55M | -14.83M | 13.41M | 11.59M | 7.81M | -20.27M | 10.12M | -9.96M | -8.73M | -25.61M | -33.12M | -46.41M | - | -75.13M | -78.48M | -44.65M | 45.23M |
| Investing Cash Flow | -12.73M | -14.41M | -9.52M | -19.40M | -19.10M | -11.00M | -12.25M | 61.96M | -6.50M | -21.67M | -13.03M | -23.86M | - | -58.28M | -141.97M | -93.14M | -53.41M |
| Financing Cash Flow | 10.27M | 43.06M | -6.92M | 8.48M | 10.69M | 30.73M | -6.53M | -43.39M | 17.82M | 53.88M | 64.18M | 130.83M | - | 31.23M | 356.92M | 56.21M | 30.02M |
| Capital Expenditure | -11.76M | -14.03M | -8.21M | -15.65M | -14.35M | -11.30M | -12.25M | -8.90M | -7.60M | -6.51M | -13.03M | -23.13M | - | -58.28M | -86.97M | -93.14M | -49.64M |
| Free Cash Flow | -17.31M | -28.86M | 5.20M | -4.05M | -6.54M | -31.57M | -2.12M | -18.86M | -16.32M | -32.12M | -46.15M | -69.54M | - | -133.41M | -165.46M | -137.79M | -4.41M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -102.19M | 136.46M | -81.58M | 21.84M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 25.00M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 67.2% | 65.7% | 59.1% | 63.1% | 60.7% | 70.9% | 65.5% | 63.3% | 67.1% | 69.0% | 68.4% | 70.8% | 64.9% | 66.4% | 64.3% | 69.4% | 69.6% |
| Operating Margin % | -8.4% | -6.9% | -12.4% | -5.0% | -35.9% | 1.0% | -130.9% | -12.8% | -8.8% | -24.5% | -41.7% | -40.6% | -52.7% | -34.5% | -30.7% | -20.1% | -7.6% |
| Net Margin % | -11.0% | -8.4% | -11.2% | -7.9% | -40.2% | -8.3% | -133.0% | -24.9% | -2.3% | -31.6% | -50.3% | -54.5% | -58.8% | -43.1% | -38.7% | -26.5% | -18.8% |
| ROE % | -17.8% | -5.4% | -9.0% | -6.3% | -47.9% | -8.6% | 488.5% | 72.1% | 8.6% | -164.9% | -130.6% | -60.8% | - | 436.4% | -238.9% | 1,144.2% | -1,153.8% |
| ROCE % | - | -3.5% | -7.9% | -3.0% | -25.7% | 0.5% | -825.5% | -28.4% | -16.4% | -22.7% | -35.4% | -29.0% | - | -31.7% | -22.9% | -19.7% | -10.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.33% | 11.33M | $106.92M |
| 2 | Braidwell LP | 4.23% | 6.53M | $61.66M |
| 3 | American Century Companies Inc | 4.22% | 6.52M | $61.56M |
| 4 | Vanguard Capital Management LLC | 3.32% | 5.12M | $48.36M |
| 5 | BNP Paribas Asset Management Holding S.A. | 2.29% | 3.54M | $33.38M |
| 6 | State Street Corporation | 2.25% | 3.48M | $32.86M |
| 7 | Jacobs Levy Equity Management, Inc. | 2.17% | 3.35M | $31.64M |
| 8 | Geode Capital Management, LLC | 2.06% | 3.19M | $30.10M |
| 9 | Royal Bank of Canada | 1.94% | 3.00M | $28.28M |
| 10 | Nuveen, LLC | 1.68% | 2.60M | $24.56M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATEC
$ATEC stock is down 8% today. Here's what we see in our data. | ATEC Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPSHAzSW42TGtLeS1HMkt2WUQxSVRvZFllZ3pLZW05ZURQdzFRU0VaNUNlMHRNZTdsZEhOQ1NvSXU3a0hiNVI2WkhiQ0EzRld0OVdGWmtkczFrTkl6UjhjMWwyWjFVMzl3a3Fhb2xNY2ZfOURwVTBRQm9MdHVQcG1aTU04T0hSdU5hSXh1Zm…
Trading Systems Reacting to (ATEC) Volatility - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcWVTY0JBV3VVa3g5TmF4NGdwQUwzd0VONlhJT2pYak9PZi02NUdlbWRvOHZlNjdVUlhpZVNqLUcyemtYTGhnZU9ZanZVY0FNYWs2elo4WTllZmxpSFRDS2JiZk9tMHR5dktlelVvWEd4NlNCenEyLVZUeUJzS09kazFSbk4weGVDbldKeD…
Alphatec Holdings, Inc. (ATEC): 12 Best Future Stocks to Buy Right Now. - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQYmRIb3FqS3cwTWpDRXIxeU9TR2JJLVp0SVFfVVBqVVlqbWJVaTgwRHhzTFlNajRBTjkyWFhnNTVQVVBod0RRSTFDVGRraTF2ckY2WU5JcEp5RlozeEJLSHk2b196Ry1OZGJGeS0wbW90U1RsY0pFSlpTbllLV1dkNGJ3eEhOcXJfd3BRTF…
Alphatec Sets Live Webcast and Analyst Q&A for Aug. 4 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNaXpUWHFXeVNpV0VHRDdxcGtQVmxjMHczTkRuQU53RTVTQ3FDN0RLLVA3aV9DZXlxM0xWQndLbXJ4YXFRYjdmSmN6Q2JseGhCOUlaTUdaWWZOazBkcEdLX25LWlkzeV9jRGJEaW9uaWNRcGc0a2xta19NbGtxQTJiOENKRmQxQXNoRHZQQ0…
Alphatec (ATEC) Stock May Trade Below Fair Value On Sales Growth - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOWUVtUFpsOVc3MUNiRDRQVkRqSlhSRzlreGhMWFU5Z1lHbW40aFdUaGtVY1IzYUN3OC1za240cG92Y0NKUGtwaTNaVWNRa2xrSTBzeXR0QTVjb1Zsc2gyZnhlU0E5a3Z6a2ZpbmcwUG4zeTZ0dldLVmpaSFdCbkE3UDNaUVFOVGRwaTE3T0…
Alphatec Stock: Straightening Its Back (NASDAQ:ATEC) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE1PMmpJcXdsMDJFdlQwMTdlRzVHZHVrN3Z3dU5qZzl5cGRhUXcxOThmVGhvei01cnk4dFRiWXFkaHN6RnpWTWoyY2JhVXhLQVhnMl81VUhiVjdtbmxtWUdndkR2MGE4YVJEZFpKdjNFT01fREExbWZ0RGtMMTQ?oc=5" target="_blank">…
ATEC — Frequently Asked Questions
What is the current share price of Alphatec Holdings, Inc. (ATEC)?
As of 2026-09-07 16:24 PDT, Alphatec Holdings, Inc. (ATEC) trades at $9.45 on NasdaqGS. Its 52-week range is $6.99 to $22.68.
What is the market capitalisation of ATEC?
Alphatec Holdings, Inc. (ATEC) has a market capitalisation of $1.45B on NasdaqGS.
What is the P/E ratio of ATEC?
ATEC trades at a trailing price-to-earnings (P/E) ratio of -13.31. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -117.85.
Is ATEC a good stock to buy?
This page provides a data-driven analysis of Alphatec Holdings, Inc. (ATEC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.